Is Technological Change In Medicine Worth It?

作者: David M. Cutler , Mark McClellan

DOI: 10.1377/HLTHAFF.20.5.11

关键词: Cost–benefit analysisPublic policyLife expectancyQuality of life (healthcare)EconomicsTechnological changePublic economicsWelfarePresent valueHealth technologyHealth policy

摘要: When costs and benefits are weighed together, technological advances have proved to be worth far more than their costs. by David M. Cutler Mark McClellan ABSTRACT: Medical technology is valuable if the of medical exceed We analyze change in five conditions deter- mine this so. In four conditions—heart attacks, low-birthweight infants, depression, cataracts—the estimated benefit much greater cost. fifth condition, breast cancer, about equal magnitude. conclude that spending as a whole increased cost care. This has many implications for public policy. I t widely accepted ac- counted bulk care increases over time. But it does not necessarily follow there- fore bad. Presumably, brings addi- tion costs—increased longevity, improved quality life, less time absent from work, so on. These need compared with before welfare statements can made. Technological bad only benefits. aggregate, health in- creased. Given then prevailing age, average newborn 1950 could expect spend $8,000 present value on his or her lifetime. The comparable amount 1990 $45,000. An infant born had life expectancy was seven years one 1950, lower lifetime disability well. 1 how improvement result care? Is component it? questions capture perhaps most critical issue economic

参考文章(25)
Zvi Griliches, Joseph P. Newhouse, Jack E. Triplett, Ernst R. Berndt, David M. Cutler, Richard G. Frank, Medical Care Prices and Output Handbook of Health Economics. ,vol. 1, pp. 119- 180 ,(2000) , 10.1016/S1574-0064(00)80162-6
Dahlia Remler, Dahlia Remler, Dahlia Remler, Mark B. McClellan, Mark B. McClellan, David M. Cutler, David M. Cutler, Joseph P. Newhouse, Pricing Heart Attack Treatments Social Science Research Network. ,(1999)
Alan D. Lopez, Christopher J. L. Murray, The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. Harvard School of Public Health on behalf of the World Health Organization and the World Bank , Distributed by Harvard University Press. ,(1996)
David M. Cutler, Mark McClellan, Joseph P. Newhouse, How Does Managed Care Do It? The RAND Journal of Economics. ,vol. 31, pp. 526- 548 ,(2000) , 10.2307/2600999
Pamela A. Sytkowski, William B. Kannel, Ralph B. D'Agostino, Changes in Risk Factors and the Decline in Mortality from Cardiovascular Disease New England Journal of Medicine. ,vol. 322, pp. 1635- 1641 ,(1990) , 10.1056/NEJM199006073222304
D. Kessler, M. McClellan, Do Doctors Practice Defensive Medicine Quarterly Journal of Economics. ,vol. 111, pp. 353- 390 ,(1996) , 10.2307/2946682
Edgar A. Peden, Mark S. Freeland, A Historical Analysis of Medical Spending Growth, 1960–1993 Health Affairs. ,vol. 14, pp. 235- 247 ,(1995) , 10.1377/HLTHAFF.14.2.235
Dennis G. Fryback, Erik J. Dasbach, Ronald Klein, Barbara E.K. Klein, Norma Dorn, Kathy Peterson, Patrica A. Martin, The Beaver Dam Health Outcomes study: Initial Catalog of Health-state Quality Factors Medical Decision Making. ,vol. 13, pp. 89- 102 ,(1993) , 10.1177/0272989X9301300202
D. M. Cutler, M. McClellan, J. P. Newhouse, D. Remler, Are Medical Prices Declining? Evidence from Heart Attack Treatments Quarterly Journal of Economics. ,vol. 113, pp. 991- 1024 ,(1998) , 10.1162/003355398555801
K. G. Manton, X. Gu, Changes in the prevalence of chronic disability in the United States black and nonblack population above age 65 from 1982 to 1999 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 6354- 6359 ,(2001) , 10.1073/PNAS.111152298